Adc Therapeutics Sa's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Adc Therapeutics Sa's ROA in the second quarter of 2026?
Adc Therapeutics Sa recorded a cumulative net loss of $-97 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -27.14%.

However, within the Healthcare sector 438 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3856, from total ROA ranking in the first quarter of 2026 at 4566.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-13.12 %	5.31 %	8.51 %	-12.88 %	-9.71 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-97	-137	-143	-167	-170
Return On Assets (TTM)	-27.14 %	-37.26 %	-39.18 %	-47.32 %	-46.75 %
ADCT's Total Ranking	# 3856	# 4566	# 4074	# 4110	# 4087
Total Assets (TTM) in million	279	287	572	290	322
Seq. Total Assets Change	-2.66 %	-49.84 %	97.48 %	-9.89 %	17.99 %
Seq. Net Income Change	-	-	-	-	-

ADCT's 5 Years Annual ROA >> Back to ADCT Management Effectiveness >> Compare ADCT ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 169
Sector	# 439
Overall	# 3647

Return On Assets Statistics
High	Average	Low
11.86 %	-28.02 %	-106.15 %
(July 31, 2005)		(Sep 30 2024)

Financial Statements
Adc Therapeutics Sa's Assets	$ 279 million	ADCT's Balance sheet
Adc Therapeutics Sa's Income	$ -17 million	Quarterly ADCT's Income Statement
ADCT's Income by Division		See ADCT's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	8.97 %	-3.76 %	-53.13 %	84.54 %	20.51 %
Total Assets in million	572	525	546	1,164	631
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-143	-158	-240	-156	-230
Annual Return On Assets	-24.93 %	-30.06 %	-44 %	-13.38 %	-36.46 %

ADCT's 5 Years Annual ROA >> Back to ADCT Management Effectiveness >> Compare ADCT ROA to its Competitors

More Return On Assets Ratios
ADCT's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ADCT's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ADCT's Competitors
Subscribers only: Roa for Adc Therapeutics Sa's Suppliers
Subscribers only: Return On Assets for ADCT's Customers

You may also want to know
ADCT's Roi	ADCT's Inventory Turnover Ratio	ADCT's Growth Rates	ADCT's Dividend Comparisons
	ADCT's Profitability Ratios	ADCT's Asset Turnover Ratio	ADCT's Dividend Growth
ADCT's Roe	ADCT's Valuation Ratios	ADCT's Financial Strength Ratios	ADCT's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-02T20:46:29+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.